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9.1
Characterisation of cardiac phenotype in genetically defined hypertrophic cardio-
myopathy.
H. Helena Tuunanen1, J. Kuusisto2, J. Toikka3, P. Ja¨a¨skela¨inen2, M. Haaparanta1, K.
Peuhkurinen2, O. Eskola1, P. Nuutila1, M. Laakso2, J. Knuuti.1 1Turku PET-Centre,
Turku, Finland, 2Kuopio University Hospital, Department of Medicine, Kuopio,
Finland, 3Tampere University Central Hospital, Department of Clinical Physiology,
Tampere, Finland
Background: Abnormalities in myocardial metabolism and mechanical performance
are known to characterize hypertrophic cardiomyopathy (HCM). This study evaluated
myocardial perfusion, oxidative and substrate metabolism in genetically homogenous
HCM patients with different phenotypic expressions.
Methods: Eight patients with HCM caused by the Asp175Asn substitution in the
alpha-tropomyosin gene underwent in fasting state myocardial blood flow, oxygen
consumption (Kmono) and free fatty acid (FFA) uptake measurements using positron
emission tomography and [15O]H20, [11C]acetate and [18F]FTHA respectively.
Echocardiographic measurements were used to assess myocardial function and work.
Efficiency of forward work was calculated.
Results: As compared to normal values, patients with HCM were characterised with
normal global perfusion but increased oxygen consumption and reduced efficiency.
Myocardial FFA uptake was within the normal range. Global perfusion and Kmono as
well as efficiency were inversely correlated with LV mass and were significantly lower
in patients with LV mass  180g (n 4) than LV mass  180 g (n 4) (p  0.05).
Global myocardial FFA uptake was not associated with degree of hypertrophy.
Typical for HCM, hypertrophy was heterogenous affecting more commonly septal wall.
At individual level, regional FFA uptake and Kmono correlated nicely in patients with
mild LV hypertrophy (R 0.73-0.99, avg 0.85) whereas the correlation was mainly
inverse in patients with more advanced hypertrophy (R 0.88-0.68, avg 0.24).
Conclusions: Genetically defined homogenous HCM patients with Asp175Asn muta-
tion in the alpha-tropomyosin gene are characterized with increased oxygen consump-
tion and reduced efficiency of forward work but normal perfusion and FFA uptake.
However, cardiac phenotypic expression is also associated with changes in perfusion,
oxygen consumption and efficiency. The patients with advanced LV hypertrophy are
characterised with uncoupling of regional oxidative metabolism and FFA utilization
indicating switch in cardiac substrate metabolism not attributable to genetic factors.
Key words: hypertrophic cardiomyopathy, myocardial metabolism, efficiency
9.2
Impaired myocardial blood flow and flow reserve associated with increased
coronary resistance in persistent idiopathic atrial fibrillation.
M. Michael Scha¨fers1, F. Range1, T. Acil2, K. Scha¨fers1, B. Brisse2, G. Breithardt2, O.
Schober1, T. Wichter.2 1University Mu¨nster, Nuclear Medicine, Mu¨nster, Germany,
2University Hospital, Cardiology, Muenster, Germany
Background: Many patients with atrial fibrillation (AF) present with signs and symptoms
of myocardial ischemia despite exclusion of coronary artery disease. In this respect a
regulatory disorder of the small vessels has been discussed. Aim of this study was to
quantify myocardial perfusion and perfusion reserve in AF patients non-invasively by
positron emission tomography and radioactive-labeled water (H215O-PET).
Methods and Results: Thirty patients (25 male, 5 female, age: 5913 years) with
persistent idiopathic AF were enrolled in this study. Using H215O-PET, myocardial
perfusion was quantified at rest, during intravenous adenosine infusion provoking the
maximal hyperaemic myocardial perfusion and during cold pressor testing (CPT) to obtain
the maximal perfusion stimulated by the endothelial response. Values were compared to
those in a group of 33 healthy volunteers (12 male, 21 female, age: 4013 years).
Resting myocardial perfusion was reduced in AF patients as compared to the control
subjects (0.890.22 vs. 1.020.25 mL/min/g; P0.026). Hyperaemic perfusion
reserve was significantly diminished in AF vs. controls (2.921.32 vs. 3.951.33
mL/min/g; P0.024). Accordingly, endothelium-stimulated myocardial blood flow was
reduced in AF patients after CPT as compared to controls (1.020.38 vs. 1.320.42
mL/min/g; P0.005). Coronary vascular resistance, calculated from myocardial blood
flow and mean arterial pressure, was significantly increased in AF patients when
compared with controls at rest (11033 vs. 9023 mmHg*mL-1*g-1*min-1;
P0.007), under adenosine infusion (4321 vs. 248 mmHg*mL-1*g-1*min-1;
P0.001) and following cold stress (11341 vs. 7621 mmHg*mL-1*g-1*min-1;
P0.001).
Conclusion: AF reduces baseline myocardial perfusion as well as stimulated myocar-
dial perfusion reserves and is associated with increased coronary resistance. Studies to
elucidate the underlying cause are warranted to give further pathophysiological insights.
9.3
Effects of candesartan on cardiac sympathetic nerve activity in patients with
congestive heart failure and preserved left ventricular ejection fraction.
S. Shu Kasama1, T. Honjo1, S. Ichikawa1, T. Toyama2, M. Kurabayashi.2 1Kitakanto
Cardiovascular Hospital, Internal Medicine, Gunma, Japan, 2Gunma University School
of Medicine, Department of Cardiovascular Medicine, Maebashi, Japan
OBJECTIVES We sought to evaluate the effects of angiotensin receptor blocker
(ARB) on cardiac sympathetic nerve activity in patients with congestive heart failure
(CHF) with preserved left ventricular ejection fraction (LVEF).
BACKGROUND Approximately 50% of patients with CHF show preservation of the
LVEF. It has been reported that ARB therapy improves cardiac sympathetic nerve
activity in CHF patients and a reduced LVEF. However, the effect of ARB therapy on
cardiac sympathetic nerve activity evaluated by 123I-meta-iodobenzylguanidine
(MIBG) scitigraphy has not been determined in CHF patients with preserved LVEF.
METHODS We selected 50 patients with nonischemic CHF and an LVEF greater than
40% who were treated with standard therapy. Twenty-five patients were randomized to
additionally receive candesartan, while the remaining 25 patients received placebo. The
delayed heart/mediastinum count (H/M) ratio, delayed total defect score (TDS), and
washout rate (WR) were determined by 123I-MIBG scintigraphy before and after 6
months of therapy. The left ventricular end-diastolic volume (LVEDV) and LVEF were
determined by echocardiography, and the plasma brain natriuretic peptide (BNP)
concentration was also measured.
RESULTS In patients receiving candesartan, TDS decreased from 288 to 238
(p0.0005), the H/M ratio increased from 1.870.24 to 2.000.22 (p0.005), and WR
decreased from 3711% to 328% (p0.005). In addition, LVEDV decreased from
11438 ml to 9027 ml (p0.05), and LVEF increased from 547% to 5810%
(p0.05). In contrast, there were no significant changes of these parameters in the
patients receiving placebo. There was a significant correlation between the changes of
123I-MIBG scintigraphic findings and the percent change of BNP from baseline to 6
months in patients receiving candesartan (TDS, r0.587, p0.005; H/M ratio,
r-0.509, p0.01; and WR, r0.602, p0.005).
CONCLUSIONS Adding candesartan to standard therapy can improve cardiac
sympathetic nerve activity and left ventricular performance in CHF patients with
preserved LVEF.
9.4
Long-term prognosis in patients with chronic ischemic left ventricular dysfunction
after viability testing with PET and revascularization.
C. Pollack1, J.P. Hellermann2, M. Namdar1, P. Koepfli1, P. T. Patrick Siegrist1, N. Bartenstein1,
U. Schurr3, R. Jenni2, P.A. Kaufmann.1 1University Hospital Zurich, Nuclear Cardiology,
Zurich, Switzerland, 2University Hospital Zurich, Cardiovascular Center, Zurich,
Switzerland, 3University Hospital Zurich, Cardiac Surgery, Cardiovascular Center,
Zurich, Switzerland
Background: Most outcome studies in patients with ischemic left ventricular dysfunc-
tion (LVD) and hibernating myocardium as assessed with PET are limited by short-term
follow-up or small patient populations.
Aim: To assess the impact of myocardial viability testing with PET and revasculariza-
tion (revasc) on long-term prognosis in a large study population with LVD.
Methods: The baseline characteristics and the follow up (f/u) of 246 consecutive patients (age
6010 years) with ischemic LVD who underwent FDG and NH3 PET scan for evaluation of
hibernating myocardium (NH3/FDG mismatch) were assessed.
Results: see table 1
Conclusion: Our results demonstrate a strong association between myocardial viability
on PET testing and improved survival after revascularization in patients with chronic
ischemic LVD. Viable tissue seems to represent a risk factor, as lack of revasculariza-
tion is associated with increased mortality. Absence of viability is associated with no
significant difference in outcomes, irrespective of treatment strategy.
Table 1.
Hibernating Hibernating No Hibernating No Hibernating
Revasc No Revasc Revasc No Revasc
n 49 38 52 107
age, years 5811 5810 599 609
gender, male 87% 82% 83% 88%
LVEF (%) 3010 2911 325 2912
3-vessel disease 80% 37% 47% 46%
mean f/u, years 4.52.4 4.22.8 4.52.2 4.32.6
annual mortality 12.0% 19.3% 11.0% 9.5%
survivors, end of f/u 63.0% 27.9% 64.0% 53.0%
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9.5
Biventricular pacing improves left ventricular synchrony irrespective of AV-delay
in patients with congestive heart failure.
P. T. Siegrist1, N. Comte1, P. Pascal Koepfli2, M. Namdar1, M. Klainguti1, C.
Brunchkhorst1, C. Scharf1, P. A. Kaufmann.1 1University Hospital Zurich, Cardiovas-
cular Center, Zurich, Switzerland, 2Cardiovascular Center, University Hospital Zurich,
Zurich, Switzerland
Background: Biventricular pacing (bivPM) in patients with heart failure results in
improved left ventricular performance through resynchronization of systolic myocardial
contraction. A prolonged AV-delay improves diastolic left ventricular filling but is
associated with increased probability of AV fusion beats that may interfere with resynchro-
nization. The relative influence of these two potentially opposing effects is unknown so far.
Aim: To assess the influence of different AV-delays on left ventricular synchrony and
left ventricular ejection fraction (EF) using multigated acquisition radionuclide ven-
triculography (MUGA).
Methods: In 12 patients with severe congestive heart failure EF and synchrony was
assessed without (noPM) and during bivPM at different AV-delays (80ms, 100ms, 120ms,
140ms, 160ms) with MUGA. Synchrony was defined by the standard deviation in the
phase-delay within the left ventricle (LV-SD). This was calculated by use of a phase-
histogram and expressed as fraction of a 360° heart cycle. EF was compared to LV-SD at
the different AV-delays using Pearson Correlation.
Results: see table 1.
Conclusion: bivPM for congestive heart failure improves left ventricular synchrony
irrespective of the chosen AV-delay. Left ventricular synchrony is closely related to EF.
Table 1
A:
AV-delay of bivPM (ms) 80 100 120 140 160 noPM
LV-SD (°) 66 68 67 69 67 76
p-values vs. noPM 0.006 .004 0.003 0.006 0.001
B:
correlation of LV-SD
with EF
0.85 0.88 0.82 0.92 0.82 0.84
p-value for correlation 0.000 0.000 0.001 0.000 0.001 0.001
A: LV-SD was significantly reduced by bivPM at any AV-delay. B: LV-SD was inversely
correlated to EF.
9.6
Selection of heart failure patients for cardiac resynchronisation therapy: Could there
be a role for equilibrium radionuclide angiography with Fourier phase analysis?
A. Cheetham, MB. Al-Housni, R. Smith, M. Mason, N. Banner, AD. Andrew Kelion.
Harefield Hospital, Nuclear Medicine Department, Harefield, United Kingdom
Background. Equilibrium radionuclide angiography (ERNA) with Fourier phase analysis could
be used to identify heart failure patients likely to benefit from cardiac resynchronisation therapy
(CRT). We compared phase indices in patients with left ventricular failure (LVF) with a “control
group” of patients post orthotopic cardiac transplantation (OCT).
Methods. 138 patients with severe LVF due to coronary disease (CAD; n19) or
dilated cardiomyopathy (DCM; n45), or who were clinically stable post OCT with
(n28) or without (n46) LV dysfunction (ejection fraction (EF) 50%) underwent
routine ERNA. A left anterior oblique projection was acquired with 32 frames per cycle.
Results. LV phase standard deviation (SD) and interventricular phase difference
(RV-LV) increased with increasing QRS duration and decreasing LV EF (Figure).
Phase values were low with little variability in normal LV OCT patients, with
progressively higher values for impaired LV OCT and LVF patients (Table). There was
little overlap between normal LV and LVF groups for SD, but more for RV-LV.
Conclusion. SD and RV-LV increase with increasing QRS and decreasing LV EF, but
the scatter implies that independent information is provided. Compared with RV-LV,
SD may provide a clearer cut-off for selecting patients for CRT.
Table
OCT healthy OCT impaired DCM CAD P
LV SD (deg) 4.3 (1.6) 7.4 (4.7) 17.3 (9.8) 20.3 (9.1) 0.001
RV-LV (deg) 6.7 (6.7) 4.3 (9.4) 2.6 (15.8) 1.8 (12.0) 0.001
Mean (SD) values of phase indices in different patient groups
Variation of LV phase SD with EF
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